MARKET

STTK

STTK

Shattuck Labs, Inc.
NASDAQ
6.29
-0.07
-1.10%
Opening 13:44 09/24 EDT
OPEN
6.34
PREV CLOSE
6.36
HIGH
6.40
LOW
6.01
VOLUME
549.62K
TURNOVER
--
52 WEEK HIGH
8.33
52 WEEK LOW
1.700
MARKET CAP
631.28M
P/E (TTM)
-12.3649
1D
5D
1M
3M
1Y
5Y
1D
Shattuck Labs management to meet with Piper Sandler
TipRanks · 21h ago
Weekly Report: what happened at STTK last week (0914-0918)?
Weekly Report · 3d ago
Weekly Report: what happened at STTK last week (0907-0911)?
Weekly Report · 09/14 09:45
Weekly Report: what happened at STTK last week (0831-0904)?
Weekly Report · 09/07 09:41
Shattuck Labs Announces Participation in Upcoming September Investor Conferences
Barchart · 09/02 15:05
Shattuck Labs: A Receptor-Side Bet On The TL1A Boom
Seeking Alpha · 09/01 11:17
Weekly Report: what happened at STTK last week (0824-0828)?
Weekly Report · 08/31 09:45
What Shattuck Labs Stock Topped the Market on Monday
The Motley Fool · 08/24 22:23
More
About STTK
Shattuck Labs, Inc. is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is engaged in developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease and other inflammatory and immune-mediated diseases. Its lead product candidate, SL-325, is a monoclonal antibody that is designed to bind to death receptor 3 (DR3) and inhibit its interaction with its ligand, TL1A. TL1A is a costimulatory ligand in the tumor necrosis factor superfamily, which activates immune responses through binding a single receptor, DR3. It is conducting a Phase I clinical trial in healthy volunteers. It is also developing SL-425, a half-life extended version of SL-325. It is also developing multiple preclinical DR3-based bispecific antibodies, which are designed to inhibit both the DR3/TL1A axis and another biologically relevant target for the treatment of patients with inflammatory bowel disease.

Webull offers Shattuck Labs Inc stock information, including NASDAQ: STTK real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, STTK stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading STTK stock methods without spending real money on the virtual paper trading platform.